Keryx (NASDAQ:KERX), a biotech company that soared in January following positive clinical trial data, released its first-quarter results after the market closed yesterday. Today, shares were down a mere 1.75%.

Earnings reports are often catalysts for stocks, so why were shares basically flat today? What upcoming events should investors keep on their radar? In the following video, health-care analyst Max Macaluso discusses Keryx's results and the main takeaways for investors.